We came across a bullish thesis on Agios Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will ...

U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat ...

Agios Pharmaceuticals’ pivot from cancer to rare diseases culminated in the $1.8 billion sale of its oncology business. But the biotech still needs capital to support a product launch and additional ...

Agios Pharmaceuticals has agreed to sell to Royalty Pharma rights to royalties on a brain cancer drug it invented and sold to Servier. Per deal terms announced Tuesday, Agios will receive $905 million ...

The average one-year price target for Agios Pharmaceuticals (NasdaqGS:AGIO) has been revised to $39.20 / share. This is an ...

Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, ...

Agios Pharmaceuticals will sell its rights to the 15% royalty it holds on potential U.S. net sales of vorasidenib to Royalty Pharma. Royalty Pharma announced this week that it will pay Agios $905 ...

Agios Pharmaceuticals Inc. has agreed to sell its oncology business to Boston’s Servier Pharmaceuticals in a deal worth up to $2 billion. Agios, of Cambridge, which has two cancer drugs on the market ...

After going it alone for the past 14 years, Agios is ready to find a dance partner to help move its pipeline forward. But as part of the hunt for a company or companies that may nod back to Agios’ ...

Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit and follow us on LinkedIn and X. Contacts: Investor Contact Morgan Sanford, Vice ...

Cambridge, Massachusetts-based Agios will market its new product, a twice-daily tablet, under the name “Pyrukynd.” The FDA’s Thursday approval covers use of the drug in adults who have an inherited ...

On Thursday, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are not regularly transfused ...